Growth Metrics

Biomerica (BMRA) Debt to Equity (2011 - 2012)

Biomerica recorded quarterly Debt to Equity of $0.01 in Q2 2012, up 242.23% quarter-over-quarter from $0.0 in Q4 2011, and up 5.68% year-over-year from $0.01 in Q2 2011.

Biomerica's Debt to Equity history runs 2 years deep, the most recent figure standing at $0.01 for Q2 2012.

  • In Q2 2012, Debt to Equity rose 5.68% year-over-year to $0.01; the TTM figure through May 2012 stood at $0.01 (up 5.68% YoY), while the FY2012 annual figure was $0.01, up 5.68% from the prior year.
  • Debt to Equity came in at $0.01 for Q2 2012 at Biomerica, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.01 in Q2 2012 to a low of $0.0 in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 0.65
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 0.64
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 0.57
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 0.42
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 0.06
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 0.95
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 0.27
10 Biomerica 7.12 Mn 5.78 Mn -44,000.00 -

Historic Data

Download Data 🔒
DateValue
May 31, 2012 0.01
Nov 30, 2011 0.00
Aug 31, 2011 0.01
May 31, 2011 0.01